NervGen Common Stock vs Other Stockholder Equity Analysis
NGEN Stock | CAD 2.90 0.10 3.33% |
NervGen Pharma financial indicator trend analysis is infinitely more than just investigating NervGen Pharma Corp recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NervGen Pharma Corp is a good investment. Please check the relationship between NervGen Pharma Common Stock and its Other Stockholder Equity accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NervGen Pharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Common Stock vs Other Stockholder Equity
Common Stock vs Other Stockholder Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NervGen Pharma Corp Common Stock account and Other Stockholder Equity. At this time, the significance of the direction appears to have totally related.
The correlation between NervGen Pharma's Common Stock and Other Stockholder Equity is 1.0. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Other Stockholder Equity in the same time period over historical financial statements of NervGen Pharma Corp, assuming nothing else is changed. The correlation between historical values of NervGen Pharma's Common Stock and Other Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of NervGen Pharma Corp are associated (or correlated) with its Other Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Stockholder Equity has no effect on the direction of Common Stock i.e., NervGen Pharma's Common Stock and Other Stockholder Equity go up and down completely randomly.
Correlation Coefficient | 1.0 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Common Stock
Other Stockholder Equity
Most indicators from NervGen Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NervGen Pharma Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NervGen Pharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. Selling General Administrative is likely to drop to about 4.9 M in 2024. Issuance Of Capital Stock is expected to grow at the current pace this year
NervGen Pharma fundamental ratios Correlations
Click cells to compare fundamentals
NervGen Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
NervGen Pharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 6.8M | 6.7M | 17.9M | 23.9M | 13.2M | 11.3M | |
Other Current Liab | 172.4K | 583.3K | 725.5K | 8.1M | 11.7M | 12.3M | |
Total Current Liabilities | 923.9K | 755.1K | 1.1M | 10.2M | 15.1M | 15.9M | |
Total Stockholder Equity | 5.8M | 5.9M | 16.8M | 13.5M | (2.0M) | (1.9M) | |
Net Tangible Assets | 5.3M | 5.4M | 16.3M | 13.0M | 15.0M | 7.7M | |
Retained Earnings | (11.1M) | (22.3M) | (35.0M) | (55.8M) | (78.2M) | (74.2M) | |
Accounts Payable | 751.6K | 171.8K | 352.5K | 2.0M | 550.4K | 672.0K | |
Cash | 4.1M | 5.6M | 16.9M | 22.5M | 11.7M | 9.9M | |
Non Current Assets Total | 509.6K | 473.4K | 475.8K | 726.7K | 720.5K | 555.8K | |
Common Stock Shares Outstanding | 25.9M | 32.1M | 39.3M | 52.6M | 59.6M | 41.5M | |
Liabilities And Stockholders Equity | 6.8M | 6.7M | 17.9M | 23.9M | 27.5M | 28.8M | |
Total Liab | 923.9K | 755.1K | 1.1M | 10.4M | 15.2M | 16.0M | |
Net Invested Capital | 5.8M | 5.9M | 16.8M | 13.5M | (2.0M) | (1.9M) | |
Total Current Assets | 6.3M | 6.2M | 17.4M | 23.1M | 12.5M | 10.7M | |
Net Working Capital | 5.3M | 5.4M | 16.3M | 12.9M | (2.6M) | (2.5M) | |
Net Debt | (4.1M) | (5.6M) | (16.9M) | (22.2M) | (20.0M) | (19.0M) | |
Cash And Short Term Investments | 4.1M | 5.6M | 16.9M | 22.5M | 25.8M | 27.1M | |
Net Receivables | 122.5K | 62.6K | 64.0K | 27.0K | 250.2K | 262.7K | |
Other Current Assets | 2.0M | 540.8K | 427.6K | 669.9K | 602.9K | 594.4K | |
Other Stockholder Equity | 1.7M | 5.3M | 9.5M | 11.8M | 13.6M | 14.3M | |
Accumulated Other Comprehensive Income | 1.7M | 5.3M | 9.5M | 11.8M | 13.6M | 14.3M | |
Capital Stock | 15.3M | 22.9M | 42.4M | 57.4M | 58.9M | 36.8M | |
Intangible Assets | 509.6K | 471.4K | 473.2K | 431.4K | 520.8K | 393.9K | |
Common Stock | 15.3M | 22.9M | 42.4M | 57.4M | 66.0M | 69.3M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NervGen Stock Analysis
When running NervGen Pharma's price analysis, check to measure NervGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NervGen Pharma is operating at the current time. Most of NervGen Pharma's value examination focuses on studying past and present price action to predict the probability of NervGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NervGen Pharma's price. Additionally, you may evaluate how the addition of NervGen Pharma to your portfolios can decrease your overall portfolio volatility.